Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Yan Hongli

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Premature Ovarian Insufficiency

Treatments: Drug: Climen 21 Tablets; Biological: hA-MSCs

Study type: Interventional

Funder types: Other

Identifiers

NCT07115082

CHEC2023-172

Details and patient eligibility

About

There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.

Full description

This clinical trial is designed to understand the safety and effectiveness of human amniotic membrane mesenchymal stem cells (hA-MSCs) in the treatment of primary ovarian insufficiency (POI). Human amniotic MSCs were infused back into the patients by intravenous injection. The trial was designed with two groups, 1) the control group by conventional hormone replacement therapy with oral Climen and 2) the stem cell treatment group by intravenous infusion of human amniotic membrane mesenchymal stem cells (hA-MSCs) combined with oral Climen hormone therapy. Patients were followed up every 2 weeks after the post-injection stem cells to observe their outcomes. The investigators focused on safety indicators, but also monitored hormone levels and signs of follicular growth to initially assess the effectiveness of the stem cells.

Enrollment: 50 estimated patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. The intention of pregnant women aged >= 20 and < 40, with normal karyotype;
2. Oligo/amenorrhea for at least 4 months;
3. Elevated FSH level >25 IU/l on two occasions >4 weeks apart;
4. Without a history of stem cell therapy and no growth hormone and/or estrogen and progesterone therapy within the previous 3 months;
5. Voluntary participation in the study with signed informed consent;

Exclusion criteria

1. Unable to follow the treatment observation process required by the trial;
2. Genetic diseases, chromosomal abnormalities, and genetic deficiency that clearly cause premature ovarian insufficiency/premature ovarian failure;
3. With breast, uterine, ovarian tumors, or any other benign or malignant tumors;
4. Allergic history to drugs or any other things;
5. Presence of genetic disorders such as Turner's syndrome, congenital malformations of the reproductive organs.
6. Have undergone ovariectomy or have organic gynaecological diseases.
7. Presence of other gynaecological endocrine diseases such as polycystic ovary syndrome.
8. Severe functional impairment of vital organs.
9. High risk factors for venous thromboembolism and abnormalities in coagulation mechanisms.
10. Attending doctor considers inappropriate to take part in.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

50 participants in 2 patient groups

Climen

Active Comparator group

Description:

Hormone replacement therapy (HRT): Take the drug Climen. Each box has 21 tablets. The first 11 tablets contain 2 milligrams of estradiol valerate each. The last 10 tablets contain 2 milligrams of estradiol valerate and 1 milligram of cyproterone acetate each. Begin taking it on the fifth day of your menstrual cycle. Take one tablet every day for seven days. Then, stop taking the medicine for seven days. After that, continue for two cycles in a row.

Treatment:

Drug: Climen 21 Tablets

hA-MSCs+Climen

Experimental group

Description:

The stem cell treatment group will be administered Climen, with the dosage and method of administration to be determined based on the control group. Concurrently, patients will receive the initial infusion of amniotic MSCs intravenously on the third day after the onset of menstruation, with a subsequent infusion administered after one month. The number of stem cells infused was calculated according to 1 million cells per kilogram of body weight.

Treatment:

Biological: hA-MSCs

Drug: Climen 21 Tablets